LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 - Clinical Trial
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
XCA37: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction (TNX-103-07)
Principal Investigator
Marat Fudim, MD, MHS
Advanced Heart Failure Specialist
Protocol Number
IRB:
PRO00119628
NCT:
NCT07288398
Phase
Phase III
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment